RxDoctor Payments Data

Noel Natoli, MD

Plastic and Reconstructive Surgery · Garden City, NYNPI 1174740401

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.6%), consulting fees and grants — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by AbbVie at 26.9% of the total. Reporting peaked in 2024 at $4,919 and has fallen 71.8% since, to $1,386 in 2025.

$11,364in general payments, 2019–2025

Across 85 payments — averaging $133.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Smith+Nephew$3K
  • Sientra, Inc.$2K
  • Kerecis Limited$2K
  • Axogen$732
  • Davol Inc.$628
  • plus $994 from 11 others

What the payments were for

  • Consulting fees$2,42021%
  • Speaking & faculty fees$540%
  • Grants$2,09518%
  • Travel & lodging$1,0749%
  • Food & beverage$4,95244%
  • Education$7697%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,364 in reported general payments places this provider in the 85th percentile of 219 plastic and reconstructive surgery providers in New York.

See all plastic and reconstructive surgery providers in New York

Medicare billing

Part B allowed, 2024
$39,341
Medicare patients
45
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone Hcl13$26

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →